What a 10-Million-Woman Medicare Study Reveals About Hormone Therapy and Longevity in Dallas
Most women have heard some version of this. Hormone therapy is fine for short-term symptom relief. But it becomes dangerous with age. Older women especially should not use it.
I’m a scientist first, and I have to look at the data. A landmark Medicare-funded study analyzed more than 10 million women. What it found should change every conversation about hormone therapy longevity in Dallas and beyond.
When researchers published these findings, they confirmed what our clinical experience at Living Well Dallas has shown for over 21 years. The relationship between hormone therapy longevity in Dallas and beyond is not the frightening picture the 2002 WHI painted. It is, in many respects, the opposite.
Here is what the data shows. And what it means for hormone therapy longevity in Dallas, where women deserve care built on current evidence — not fear.
About the Study — Hormone Therapy Longevity Research at Scale
Researchers published the study in Menopause, the journal of The Menopause Society. For supporting data, the Danish Osteoporosis Prevention Study 16-year follow-up on PubMed shows consistent cardiovascular and mortality benefits for women who continued therapy.
Researchers published the study in Menopause, the journal of The Menopause Society. Medicare funded it — the US federal health insurance program for adults 65 and older. The dataset covered more than 10 million women, with longitudinal follow-up tracking outcomes over time.
The population matters. These are exactly the women clinicians treat most cautiously. Older. Postmenopausal. Many well past the conventional “critical window.” The central question: does hormone therapy use in this population affect mortality?
Outcomes measured: all-cause mortality, cardiovascular mortality, and cancer mortality. This is real-world evidence at scale. It tracks what actually happens to millions of women — those who used hormone therapy and those who didn’t — over years of follow-up.
What the Study Found
The headline finding: women using hormone therapy had significantly lower all-cause mortality compared to women not using it.
This goes beyond quality of life or symptom relief — though hormone therapy improves both. This is about survival. Women who continued hormone therapy lived longer.
Cardiovascular mortality showed a meaningful reduction in hormone therapy users — consistent with the extensive biological evidence that estrogen is cardioprotective when the vascular endothelium is still responsive.
Cancer mortality was not elevated in hormone therapy users. This is a direct rebuttal of the fear that drove 20 years of hormone avoidance. The absolute breast cancer signal from the WHI — which caused the mass discontinuation — has been substantially recontextualized by subsequent research. This large-scale mortality data reinforces that picture.
The consistent pattern across the dataset: hormone therapy users outlived their non-using peers. That finding reframes the hormone therapy longevity conversation for Dallas women and beyond. In a population of more than 10 million women.
The Timing Hypothesis, Revisited
Conventional guidance has long said: don’t start hormone therapy after 65, or more than 10 years after menopause. The reasoning was sound — initiating hormones into an already-established inflammatory, atherosclerotic environment carries a different risk profile than initiating early.
This caution about initiating late remains reasonable. The Medicare study adds an important nuance. Women who continued hormone therapy — starting within the appropriate window and maintaining it into older age — showed the survival advantage. This is a different question from starting for the first time at 70.
The Danish Osteoporosis Prevention Study 16-year follow-up confirms this. Finnish national cohort data agrees. Women who continued hormone therapy beyond the conventional “stop at 5 years” cutoff showed cardiovascular and mortality benefits. Women who stopped did not show the predicted harms.
Among hormone-literate practitioners, the clinical consensus is clear. For women who started therapy in the appropriate window and tolerate it well, no evidence-based justification exists for arbitrary age-based discontinuation. Clinicians should individualize the question — based on ongoing benefit, risk profile, and patient goals.
What Hormone Therapy Longevity Research Means for Dallas Women Over 60, 65, 70
The framing shifts with this data. The question is no longer just “is HRT safe?” The more complete question is: what is the risk of not using hormones?
For Dallas women who started therapy appropriately and continue it, the hormone therapy longevity data supports that choice. Regular evaluation of risk factors matters. Arbitrary cutoffs do not. — with regular evaluation of risk factors, not with arbitrary cutoffs.
Many women were told to stop hormones at 5 years or at 60. Their symptoms resolved. Their doctor got nervous. Whether resuming or continuing serves their long-term health goals is worth a genuine clinical conversation.
Route of delivery matters more, not less, with age. Transdermal estrogen bypasses first-pass liver metabolism, eliminating the cardiovascular and thrombosis risk signals associated with oral estrogen. This is particularly important in older women.
Bioidentical progesterone vs. synthetic progestin: The distinction between bioidentical micronized progesterone and MPA (used in the WHI) becomes even more clinically relevant with age. The adverse signals in the WHI were largely driven by the synthetic progestin component. Bioidentical progesterone does not carry the same profile.
At Living Well Dallas, our approach for women over 60 is individualized, transdermal when possible, and bioidentical — calibrated to the current evidence.
The Hormone Therapy Longevity Conversation Your Dallas Doctor May Not Be Having
Most primary care physicians and OB-GYNs practicing today received no meaningful hormone training update after 2002. The guidelines that crystallized from the WHI’s misinterpretation embedded themselves in practice. They are slow to change.
What’s Driving the Outdated Guidance
Women hear to stop hormones at 5 years — based on misapplied risk data. They hear they’re “too old” — based on no current evidence. Clinicians set arbitrary cutoffs with no basis in current literature. And denied a conversation about longevity that the data clearly supports.
At Living Well Dallas, hormone therapy longevity in Dallas is a real clinical conversation we have with women every week. The data supports it. Our clinical experience supports it. We practice on current evidence — not 2002 guidelines. — not 2002 guidelines. — not 2002 headlines. We have been doing this work for over 21 years.
Read our foundational article on HRT safety and what the research actually says. Explore our bioidentical hormone therapy program. Take our hormone quiz as a starting point. Our brain health resources also speak to the cognitive longevity picture.
For a complementary perspective on timing, read our article on starting hormone therapy at 70.
Ready to find out if hormone therapy is right for you? Living Well Dallas has been helping women in the Dallas area reclaim their health for over 21 years. Schedule your discovery call today at livingwelldallas.com/contact/ or call us at 972-930-0260.
About the Author Lauryn Pitts, AGNP-C is a board-certified Adult-Gerontology Nurse Practitioner at Living Well Dallas, specializing in functional medicine, bioidentical hormone therapy, and women’s health.
Living Well Dallas | Dallas, TX | 972-930-0260 | livingwelldallas.com
All clinical information in this article should be reviewed by your healthcare provider. Individual health circumstances vary. This article is for educational purposes and does not constitute medical advice.